Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4 Purity >99.5% E.E >99.5%

Short Description:

Name: Boc-3-Hydroxy-1-Adamantyl-D-Glycine

CAS: 361442-00-4

Purity: >99.5% (GC) E.E: >99.5%

Appearance: White or Off-White Crystalline Powder

Intermediate of API (CAS: 361442-04-8)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Related Intermediates
CAS 361442-04-8
CAS 945667-22-1
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester CAS 361440-67-7
2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid CAS 709031-28-7

Chemical Properties:

Chemical Name	Boc-3-Hydroxy-1-Adamantyl-D-Glycine
Synonyms	(2S)-2-((tert-Butoxycarbonyl)amino)-2-(3-Hydroxyadamantan-1-yl)acetic Acid
CAS Number	361442-00-4
CAT Number	RF-PI1989
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C17H27NO5
Molecular Weight	325.40
Boiling Point	497.3±20.0℃
Density	1.296
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Off-White Crystalline Powder
Water (K.F)	<0.50%
Loss on Drying	<1.00%
Residue on Ignition	<0.50%
Single Impurity	<0.50%
Total Impurities	<0.50%
E.E	>99.5%
Purity	>99.5%
Infrared Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Boc-3-Hydroxy-1-Adamantyl-D-Glycine (CAS: 361442-00-4) is an intermediate of API (CAS: 361442-04-8). API (CAS: 361442-04-8) is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. It is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is not for treating type 1 diabetes. It is sometimes used in combination with other diabetes medications. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor.